Business Model
Value Proposition Model
- Axis MedTech will hold a number of interests that each represent a material opportunity to generate a return that is a multiple of the initial capitalisation
- The Board of each subsidiary will have representation from Axis
- Axis will have consent rights over budget and material changes thereto over subsidiaries
- Subsidiaries will agree milestones prior to investment and will be required to deliver against these to access further funding, thereby minimising downside risk for investors
- Maintaining each technology as separate entities maintains flexibility in value realisation, optimising the eventual outcome
- Target return for each subsidiary will be 5x in five years
